The discovery of novel molecular-based prognostic markers for thyroid cancer, such as RET-PTC, RAS, BRAF (V600E), PTEN and TERT mutations, are among the most notable developments in thyroid cancer-related medicine [33]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.